Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease

Blood

Volumn 110, Issue 10, 2007, Pages 3804-3813

  Chen, Xiao ^a   Vodanovic Jankovic, Sanja ^a   Johnson, Bryon ^a   Keller, Melissa ^a   Komorowski, Richard ^a   Drobyski, William R ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Bone Marrow Transplant Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TRANSCRIPTION FACTOR FOXP3;

ACUTE DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE COURSE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; TH1 CELL;

EID: 36348980530     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-05-091074     Document Type: Article

References (54)

1. Glucksberg H, Storb R, Fefer A. Clinical manifestations of graft versus host disease in human recipients of marrow from HLA-identical sibling donors. Transplantation. 1974;18:295-304.
2. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol. 2004;25:435-454.
3. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation: A study of 53 long-term-surviving patients. Transplantation. 1988;46:238-240.
4. Rouquette-Gally AM, Boyeldieu D, Gluckman E, Abuaf N, Combrisson A. Autoimmunity in 28 patients after allogeneic bone marrow transplantation: comparison with Sjogren's syndrome and scleroderma. Br J Haematol. 1987;66:45-47.
5. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant. 1998;22:873-881.
6. Mackey JR, Desai S, Larratt L, Cwik V, Nabholtz JM. Myasthenia gravis in association with allogeneic bone marrow transplantation: clinical observations, therapeutic implications and review of literature. Bone Marrow Transplant. 1997;19:939-942.
7. Drobyski WR, Potluri J, Sauer D, Gottschall JL. Autoimmune hemolytic anemia following T cell depleted bone marrow transplantation. Bone Marrow Transplant. 1996;17:1093-1099.
8. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health Consensus Development Project on criteria for clinical trails in chronic graft versus host disease, I: diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945-955.
9. Tivol EA, Komorowski R, Drobyski WR. Emergent autoimmunity in graft versus host disease. Blood. 2005;105:4887-4893.
10. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft versus host disease. J Clin Invest. 1998;102:1882-1891.
11. + T cells induce or protect chronic intestinal inflammation in C.B-17 scid mice. Int Immunol. 1993;5:1461-1471.
12. + T cells. J Exp Med. 1993;178:237-244.
13. Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft versus host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood. 2006;108:2867-2873.
14. Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Med. 13:350-365.
15. Snyder LD, Palmer SM. Immune mechanisms of lung allograft rejection. Sem Resp Crit Care Med. 2002;27:534-543.
16. + regulatory T cells limit Th1-autoimmunity by inducing IL-10 producing T cells following human lung transplantation. Am J Transplant. 2006;6:1799-1808.
17. Regauer S. Immune dysregulation in lichen sclerosus. Eur J Cell Biol. 2005;84:273-277.
18. Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology. 2005;44:274-279.
19. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clones, I: definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1985;136:2348-2357.
20. + cytotoxic T lymphocyte clones from a patient with severe graft versus host disease after allogeneic bone marrow transplantation: implications for graft versus leukemia reactivity. Blood. 1995;86:2821-2828.
21. Ochs LA, Blazar BR, Roy J, Rest EB, Weisdorf DJ. Cytokine expression in human cutaneous chronic graft versus host disease. Bone Marrow Transplant. 1996;17:1085-1092.
22. Ritchie D, Seconi J, Wood C, Walton J, Watt V. Prospective monitoring of tumor necrosis factor α and interferon γ to predict the onset of acute and chronic graft versus host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2005;11:706-712.
23. Körholz D, Kunst D, Hempel L, et al. Decreased interleukin 10 and increased interferon-γ production in patients with chronic graft versus host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19:691-695.
24. Kolls JK, Linden A. Interleukin 17 family members and inflammation. Immunity. 2004;21:467-476.
25. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6:1123-1132.
26. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133-1141.
27. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol. 2006;177:566-573.
28. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17 deficient mice. J Immunol. 2003;171:6173-6177.
29. Jovanovic DV, Di Battista JA, Martel-Pelletier J, et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-1β and TNF-α by human macrophages. J Immunol. 1998;160:3513-3521.
30. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin 17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med. 1996;183:2593-2603.
31. Imamura M, Hashino S, Kobayashi H, et al. Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin 6, interferon gamma, and tumor necrosis factor alpha in graft versus host disease. Bone Marrow Transplant. 1994;13:745-751.
32. Barak V, Levi-Schaffer F, Nisman B, Nagler A. Cytokine dysregulation in chronic graft versus host disease. Leuk Lymphoma. 1995;17:169-173.
33. Axtell RC, Xu L, Barnum SR, Raman C. CD5-CK2 binding/activation-deficient mice are resistant to experimental autoimmune encephalomyelitis: protection is associated with diminished populations of IL-17 expressing T cells in the central nervous system. J Immunol. 2006;177:8542-8549.
34. Miura Y, Thoburn CJ, Bright EC, et al. Association of Foxp3 regulatory gene expression with graft versus host disease. Blood. 2004;104:2187-2193.
35. + regulatory T cells in patients with chronic graft versus host disease. Blood. 2005;106:2903-2911.
36. + regulatory T cells are numerically deficient in acute and chronic GVHD. Blood. 2006;107:1717-1723.
37. high T cells do not correlate with the establishment of long term tolerance after allogeneic stem cell transplantation. Exp Hematol. 2005;33:894-900.
38. Arimoto K, Kadowaki N, Ishikawa T, Ichinohe T, Uchiyama T. Foxp3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graft versus host disease after allogeneic stem cell transplantation. Int J Hematol. 2007;85:154-162.
39. - precursors. Am J Transplant. 2004;4:1614-1627.
40. - T cells through foxp3 induction and down regulation of Smad7. J Immunol. 2004;172:5149-5153.
41. H17 and regulatory T cells. Nature. 2006;441:235-238.
42. + T cell-mediated suppression by dendritic cells. Science. 2003;299:1033-1036.
43. + T cell regulatory functions. J Immunol. 2007;178:271-279.
44. Cavet J, Dickinson AM, Norden J, Taylor PRA, Jackson GH, Middleton PG. Interferon γ and interleukin 6 gene polymorphisms associate with graft versus host disease in HLA-matched sibling bone marrow transplantation. Blood. 2001;98:1594-1600.
45. Socie G, Loiseau P, Tamouza R, et al. Both genetic and clinical factors predict the development of graft versus host disease after allogeneic hematopoietic stem cell transplantation. Transplantation. 2001;72:699-706.
46. + regulatory T cells and for expansion of these cells. J Immunol. 2007;178:2018-2027.
47. + regulatory T cell function. J Exp Med. 2002;196:851-857.
48. + regulatory T cells by interleukin 2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med. 2005;201:723-735.
49. Abu-Ghosh A, Goldman S, Slone V, et al. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft versus host disease during the first 100 days following unrelated umbilical cord blood transplantation. Bone Marrow Transplant. 1999;24:535-544.
50. Imamura MS, Hashino S, Kobayashi H, et al. Hyperacute graft versus host disease accompanied by increased serum interleukin 6 levels. Int J Hematol. 1994;60:85-89.
51. Rochman I, Paul WE, Ben-Sasson SZ. IL-6 increases primed cell expansion and survival. J Immunol. 2005;174:4761-4767.
52. Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26:371-381.
53. Parkman R. Clonal analysis of murine graft-vs-host disease, I: phenotypic and functional analysis of T lymphocyte clones. J Immunol. 1986;136:3543-3548.
54. DeClerck Y, Draper V, Parkman R. Clonal analysis of murine graft-vs-host disease, II: leukokines that stimulate fibroblast proliferation and collagen synthesis in graft-vs-host disease. J Immunol. 1986;136:3549-3552.